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SINTESIS DAN KAJIAN AKTIVITI SEBATIAN-SEBATIAN NOVEL 
DISPIRO PIROLIDINA SEBAGAI AGEN ANTIMIKROBAKTERIAL 
BERPOTENSI 
 
ABSTRAK 
 
Sekumpulan dispiro pirolidina yang mengandungi lima puluh dua sebatian 
telah berjaya disintesis dengan menggunakan penambahan siklo 1,3 dwikutub. 
Tindak balas ini terbukti sangat regioselektif, menghasilkan satu set regioisomer 
sahaja sebagai produk. Sebatian-sebatian ini telah dikenalpasti melalui pelbagai 
kaedah instrumentasi seperti CHN, NMR, spektrometri jisim dan analisis sinar-X. 
Aktiviti anti-mikrobakteria bagi dispiro pirolidina yang baru disintesiskan telah diuji 
terhadap strain Mycobacterium tuberculosis H37RV dengan mnggunakan asai 
“BacTiter-Glo Microbial Cell Viability”. Sebatian 3c, atau 4´-(4-bromofenil)-1´-
metilldispiro[asenaftalin-1,2´-pirolidina-3´,2˝-indane]-2,1˝(1H)-dion merupakan 
sebatian yang paling aktif, dengan IC50 pada 2.20 µM dan MIC pada 12.5 µM. 
Berbanding dengan drug-drug rujukan, sebatian 3c adalah lebih aktif berbanding 
sikloserin dan pirimetamin, sebanyak 10.7-, 11.0-kali ganda bagi IC50 dan lebih 
daripada 8 ganda bagi MIC. Sebatian 3c turut mempamerkan aktiviti yang setanding 
dengan etambutol tetapi kurang aktif berbanding isoniazid. Ujian sitoktosik telah 
dijalankan ke atas Hs27 dan fibroblas kolorektal primer untuk memeriksa toleransi 
sebatian-sebatian aktif ini terhadap sel-sel manusia. Sebatian utama 3c dibuktikan 
tidak bertoksik sehingga 250 µM dan mencatatkan indeks pemilihan yang baik, 
iaitu >20. Analisis penambatan molekul telah dilakukan untuk memahami interaksi-
interaksi yang penting antara sebatian yang aktif dengan sasaran enzim, iaitu protein 
xxviii 
 
pembawa enoil-asil reduktase (InhA). Kumpulan sebatian ini didapati dicantumkan 
secara berkomputer pada tapak substrat, dan sebatian-sebatian ini menunjukkan 
potensi untuk bertanding dengan substrat asid lemak dan merencat enzim tersebut. 
Sebatian 3c terutamanya, menunjukkan rangkaian ikatan hidrogen yang penting pada 
kdua-dua asid amino pemangkin Tyr 158 dan faktor pembawa nukelotida yang 
merupakan ciri terpelihara bagi perencat yang dikenalpasti setakat ini. Untuk 
menyokong kajian in silico ini, asai ikatan protein-ligan secara langsung telah 
digunakan dengan berdasarkan pendarfluor intrinsik triptofan daripada protein ini. 
Ikatan 3c kepada InhA telah mengubahkan konformasi protein ini dan menyebabkan 
pelindapkejutan pendarfluor yang bergantung pada kepekatan dan masa. Dengan 
keperluan segera agen antituberkular baharu, kajian ini telah menunjukkan dispiro 
pirolidina merupakan sebatian pemula yang praktikal untul penemuan ubat-ubatan 
TB.    
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SYNTHESIS AND ACTIVITY STUDIES OF NOVEL DISPIRO 
PYRROLIDINE COMPOUNDS AS POTENTIAL ANTIMYCOBACTERIAL 
AGENTS 
 
ABSTRACT 
 
A mini library of fifty two highly functionalized dispiro pyrrolidines were 
synthesized successfully using 1,3-dipolar cycloaddition. This reaction is proved to 
be highly regioselective, giving only one set of regioisomer as product. These 
compounds were characterized using various instrumental methods such as CHN, 
NMR, mass spectrometry and X-ray analysis. The antimycobacterial activity of the 
newly synthesized dispiro pyrrolidines were tested against Mycobacterium 
tuberculosis H37RV strains using BacTiter-Glo Microbial Cell Viability assay. 
Compound 3c, or 4´-(4-bromophenyl)-1´-methyldispiro[acenaphthylene-1,2´-
pyrrolidine-3´,2˝-indane]-2,1˝(1H)-dione was found to be the most potent among all, 
with IC50 of 2.20 µM and MIC of 12.5 µM. Comparing with standard drugs, 
compound 3c was found to be more potent than cycloserine and pyrimethamine by 
10.7-, 11.0-fold at IC50 and more than 8-fold at MIC. Compound 3c also exerted a 
comparable activity with ethambutol but less potent when compared to isoniazid. 
Cytotoxicity study was performed using Hs27 and primary colorectal fibroblasts to 
screen the tolerability of the active compounds in human cells. The lead compound 
3c was proven to be non-toxic up to 250 µM and recorded a good selectivity index 
of >20. Molecular docking analysis was carried out to understand the important 
interactions of the active compounds with the target enzyme, enoyl-acyl carrier 
protein reductase (InhA). This class of compounds were found to dock at the 
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substrate binding site, which can potentially compete with the fatty acyl substrate and 
inhibit the enzyme. Compound 3c especially, displayed the important dual hydrogen 
bonding network with catalytic residue Tyr 158 and the nucleotide cofactor, which is 
a conserved feature in most of the known inhibitors identified so far. To support the 
in silico study, direct protein-ligand binding assay was used based on the intrinsic 
tryptophan fluorescence of the protein. The binding of 3c to InhA resulted in a 
conformational change of the protein, causing concentration- and time-dependent 
fluorescence quenching. With the urgent need of new antitubercular agents, these 
findings have established dispiro pyrrolidines as a practical lead for TB drug 
discovery. 
 
1 
 
CHAPTER ONE 
INTRODUCTION 
 
1.1 Tuberculosis 
1.1.1  Overview 
Tuberculosis (TB) remains one of the biggest public health problems in the 21st 
century. It ranks as the second leading cause of death from an infectious disease 
worldwide after AIDS. India and China have accounted for approximately 38% of 
the world’s TB cases (World Health Organization, 2013). In spite of the availability 
of highly efficacious treatment for decades, one-third of the world’s population still 
harbour a latent form of Mycobacterium tuberculosis, with the risk of reactivation of 
about 10% over the lifetime (Villemagne et al., 2012; Stead, 1967). The WHO report 
estimated almost 9 million cases and 1.5 million TB deaths in 2013, including 0.36 
million people who were HIV-positive as well (World Health Organization, 2014a). 
In Malaysia, the current estimated incidence was 99 per 100,000 population, with the 
number of new TB cases increased from 15,000 in 2005 to 23,417 in 2013 (World 
Health Organization, 2015; Rashid Ali et al., 2015). For HIV patients with latent (or 
dormant) form of TB, the risk to develop active TB is higher due to the lack of 
immune capability to suppress the proliferation of the bacilli. Studies have found that 
HIV-positive patients are 20-30 times more likely to develop TB than HIV-negative 
individuals (Kwan and Ernst, 2011). To make matters worse, multiple drug resistant 
(MDR) and extensively drug resistant (XDR) strains of TB are on the rise (Gandhi et 
al., 2010). In 2013 there were an estimated of 480, 000 people who developed MDR-
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TB, and 9% of them were diagnosed with XDR-TB as well. Globally there were total 
100 countries that have been reported with XDR-TB cases (World Health 
Organization, 2014a). The emergence of these drug resistant strains as well as the co-
infection of HIV have heightened the need for development of new drugs to combat 
this disease.  
 
 
1.1.2 Mycobacterium tuberculosis 
In 1882, Robert Koch identified Mycobacterium tuberculosis (Mtb) as the causative 
agent of TB. This Mycobacterium family has over 60 species, with only a few like 
Mtb, Mycobacterium africanum, Mycobacterium bovis, Mycobacterium microti and 
Mycobacterium avium that can lead to human diseases (Lawn and Zumla, 2011; 
Sarkar and Suresh, 2011). Mtb is an aerobic, non-encapsulated and non-motile rod-
shaped bacterium. It grows most successfully in tissues with high oxygen content, 
and that is the reason why Mtb complexes are found mostly in the well-aerated upper 
lobes of lungs (Todar, 2009). Although Mtb contains peptidoglycan in its cell wall 
but it is neither classified as Gram-positive nor Gram-negative bacterium. This is due 
to the unusual, waxy coating on its cell surface that makes the cell impermeable to 
Gram staining. Instead, acid fast method is used to stain the bacterium since it resists 
decolourisation with acidified organic solvents once being stained (Lawn and Zumla, 
2011). 
 
The primary mode of transmission of Mtb is through air in aerosolized form. For 
example, inhalation of a few droplet nuclei of 2–5 µm containing as few as 1–3 
bacilli will lead to TB infection (Koul et al., 2011). After inhaling, these bacilli are 
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mainly engulfed by alveolar macrophages. The activated macrophages kill the 
bacteria by phagolysosomes whereas in naïve macrophages, phagosomes containing 
bacilli do not mature and will lead to primary infection (Deretic and Fratti, 1999). 
There are two possibilities at this stage in naïve macrophages: Mtb either multiplies 
intracellularly which leads to TB infection, or the bacteria are able to evade the host 
immune system and remain as dormant. The dormant stage will be reactivated into 
second infection when the host immunity is compromised (Sarkar and Suresh, 2011). 
 
 
 
Figure 1.1 Scanning electron micrograph of Mycobacterium tuberculosis ranges 
in length between 2 - 4 microns, and a width between 0.2 - 0.5 
microns (Adapted from Butler, 2006). 
 
 
1.1.3 Current TB drug therapy  
TB treatment is challenging and requires effective treatment regimens and follow-up 
support (Zumla et al., 2013). Mtb is a slow growing pathogen and thus administration 
of a combination of drugs for an extended period is required to achieve effective 
treatment and to prevent the emergence of drug-resistant strains (Craig, 1997). The 
history of first-line TB treatments began from monotherapy of streptomycin in 1946, 
and gradually evolved to multidrug treatment regimens of 24 months or more, until 
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the current short course, directly observed therapy (DOTS) for at least 6 months (Fox 
et al., 1999; Wells et al., 2013). DOTS, is currently the best therapy program to treat 
TB patients, with cure rate of more than 95%. However DOTS alone is not efficient 
in areas with high incidence of drug-resistant strains, with cure rate of merely 50% 
(Zhang, 2005; Kimerling et al., 1999).  
 
Current TB chemotherapy uses a combination of first-line drugs, starting with an 
intensive phase of 2 months of four drugs: isoniazid (INH), rifampicin (RIF), 
pyrazinamide (PZA) and ethambutol (EMB), followed by 4 months of continuation 
phase of INH and RIF (Blumberg et al., 2003). If the treatment fails in the case of 
bacterial drug resistance or intolerance of one of the first-line drugs, second-line 
drugs such as fluoroquinolones, cycloserine, kanamycin, para-aminosalicylate and 
ethionamide will be administered. These second-line drugs are usually more toxic, 
less effective and require longer duration of treatment than first-line drugs. 
Furthermore, some of these second-line drugs are not available in many poorer 
regions (van den Boogaard et al., 2009).    
 
To gain insight into the mechanisms of the available TB drugs, a brief description of 
the first-line and second-line antitubercular agents are given as follow: 
 
1.1.3(a) First-line TB drugs 
(i) Isoniazid (INH) 
Since its discovery in 1952, isoniazid (INH) (Figure 1.2) remains one of the most 
important first-line anti-TB drugs. It paved a major milestone in TB chemotherapy 
due to its high efficacy and mild side effects. More importantly, it is relatively 
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inexpensive. INH shows high early bactericidal activity against rapidly dividing 
mycobacteria and kills about 95% of organisms in the first two days of treatment. 
However when the mycobacteria are in a slow or non-growing state, INH will 
become bacteristatic and is no more effective than other drugs at this period 
(Mitchison, 2000). INH is a prodrug that requires activation by catalase-peroxidase 
hemoprotein, KatG to produce a range of highly reactive species. These reactive 
oxygen species and organic radicals will then attack multiple targets in Mtb (Zhang, 
2005). The primary target of activated INH is enoyl-acyl carrier protein reductase (or 
InhA), an essential enzyme in FAS II system which involves in mycolic acid 
synthesis (Banerjee et al., 1994). INH resistance is the most common form among 
anti-TB drugs, at the frequency of 1 in 10
5-6 
bacilli in vitro (Karakousis, 2009). 
Resistance mutations mostly happen in the target gene, InhA and in the activating 
enzyme, KatG (Global Alliance for TB Drug Development, 2008). 
 
 
 
Figure 1.2 Chemical structure of isoniazid. 
 
 
(ii) Rifampicin (RIF) 
Rifampicin (RIF) or rifampin (Figure 1.3) is a broad-spectrum semisynthetic 
macrocyclic antibiotic produced by Streptomyces mediterranei (Craig, 1997). It was 
introduced in 1967 as a drug of choice for TB treatment. It is categorized as the 
bactericidal agent and is active against both replicating and non-replicating 
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mycobacteria. The activity against the latter is thought to shorten the duration of TB 
therapy from 12-18 months to 9 months (Mitchison, 1985).   RIF inhibits the 
bacterial RNA synthesis by binding to the β-subunit of the DNA-dependent RNA 
polymerase which is encoded by rpoB (McClure and Cech, 1978; Zhang, 2005). It 
does not inhibit mammalian enzymes. RIF-resistant Mtb involves alterations of RNA 
polymerase. There is approximately 96% of mutants occur in 81-bp region of rpoB 
gene, which is the RIF resistance-determining region (RDR) (Telenti et al., 1993). 
 
 
 
Figure 1.3 Chemical structure of rifampicin. 
 
 
(iii) Pyrazinamide (PZA)  
Pyrazinamide (PZA) (Figure 1.4) is a synthetic analogue of nicotinamide that was 
first chemically synthesized in 1936 by Dalmer and Walter. It appeared as a potential 
anti-TB drug in 1952 (Zhang and Mitchison, 2003). It has high in vivo sterilizing 
activity and represents the only first-line drug that kills the persisting tubercle bacilli. 
It is added to the initial intensive phase of chemotherapy and plays a role in reducing 
the treatment duration from 9 months to 6 months (Craig, 1997). The mechanism of 
action of PZA is the least poorly understood among all anti-TB drugs. PZA is a 
prodrug that requires activation by PZase/nicotinamidase enzyme (encoded by pncA 
gene) to form pyrazinoic acid (POA) (Scorpio and Zhang, 1996). POA that is formed 
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initially in neutral cytoplasmic environment has no activity against mycobacteria. 
However under acidic conditions it is converted to uncharged protonated POA that 
permeates the cells through membrane, where it accumulates and kills the bacteria 
(Zhang and Mitchison, 2003). Mutation in pncA is a major mechanism of PZA 
resistance in Mtb (Marttila et al., 1999). 
 
 
 
Figure 1.4 Chemical structure of pyrazinamide. 
 
 
(iv) Ethambutol (EMB) 
Ethambutol (EMB) (Figure 1.5) is a synthetic compound that was reported to show 
antimycobacterial activity in 1961 and has been prescribed in TB treatment since 
1966. EMB is bacteriostatic against actively growing bacteria and it has been 
reported to inhibit several Mtb cellular pathways. The primary target of EMB is the 
biosynthesis of arabinogalactan, a major polysaccharide of mycobacterial cell wall 
(Takayama and Kilburn, 1989). It inhibits the polymerization of the arabinan 
component of arabinogalactan and of lipoarabinomannan, via inhibition of three 
arabinosyltransferases: embA, embB and embC (Goude et al., 2009). Majority of the 
EMB-resistant clinical isolates relate to point mutations in embB, with about 60% of 
the isolates carry a mutation in codon 306 (Sreevatsan et al., 1997; Plinke et al., 
2006). 
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Figure 1.5 Chemical structure of ethambutol. 
 
 
1.1.3(b)    Second-line TB drugs 
Second-line TB drugs (Figure 1.6) are considered as reserve therapy and are 
administered under special conditions such as the treatment of drug-resistant strains. 
p-Aminosalicylic acid represented one of the first TB antibiotics but its use as first-
line regimen was discontinued after the discovery of drugs which are more potent 
such as RIF. It is still used as part of the treatment for XDR-TB although its 
mechanism of action has not been clearly elucidated (Jnawali and Ryoo, 2013). 
Aminoglycosides (such as amikacin and kanamycin) and cyclic polypeptides (such 
as capreomycin) are important injectable drugs used to treat MDR-TB by interfering 
with the protein synthesis of mycobacteria (Zhang, 2005). Fluoroquinolones (FQs) 
such as ciprofloxacin, ofloxacin and levofloxacin have broad-spectrum antimicrobial 
activity and are known as bactericidal antibiotics (Wang et al., 2006; Emmerson and 
Jones, 2003). FQs inhibit the DNA synthesis of Mtb by targeting DNA gyrase, the 
sole type II topoisomerase in mycobacteria (Aubry et al., 2004). Analogues of INH 
such as ethionamide and prothionamide are also prodrugs that require bioactivation 
by enzyme EthA. They inhibit the same target as INH, which is InhA gene (Banerjee 
et al., 1994). Cycloserine is an analogue of amino acid ᴅ-alanine that is 
recommended to treat MDR- and XDR-TB in the DOTS-Plus management plan 
(World Health Organization, 2011). It inhibits the synthesis of peptidoglycans which 
are essential in bacterial cell wall formation (Jnawali and Ryoo, 2013). 
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Figure 1.6 Structures of some second-line drugs for TB treatment. 
 
 
1.1.4 Challenges in TB treatment  
Although DOTS has proven to be highly efficient, the lengthy and complicated 
treatment makes patients compliance difficult. This noncompliance is the main 
reason that causes the development of drug-resistant strains, which poses a 
significant threat to the treatment and control of this disease (Zhang, 2005). MDR-
TB are defined as strains that are resistant to first line drugs isoniazid (INH) and 
rifampicin (RIF); whereas XDR-TB are strains that are resistant not only to INH and 
RIF, but also to any fluoroquinolones and at least one of the three injectable second-
line drugs: amikacin, kanamycin and capreomycin (Chiang et al., 2010). Currently 
MDR-TB is treated by a combination of a few drugs with duration of therapy for 18-
24 months (Gandhi et al., 2010). This suboptimal therapy is less effective and causes 
approximately 30% of patients suffering from treatment failure (Mitnick et al., 2003). 
Treatment of XDR-TB is even more challenging. Only limited options of regimens 
can be used to treat XDR-TB since the bacilli are resistant to most of the available 
first-line and second-line drugs.  
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Starting from the 1980s, the growing pandemic of HIV/AIDS has fuelled a surge in 
TB cases globally, especially in the African region (World Health Organization, 
2013). The frequent TB-HIV co-infection has further complicated the selection of an 
appropriate treatment. The main pharmacokinetic interaction between anti-TB agents 
and antiretrovirals is rifampicin induces a number of drug-metabolising enzymes, 
thus increases the expression of the hepatic cytochrome (CYP) P450 oxidase system 
(Niemi et al., 2003). This CYP induction leads to sub-therapeutic concentrations of 
many co-medications such as HIV protease inhibitors (Mallolas et al., 2007). Besides 
that, the overlapping toxic effects increase safety concerns for TB-HIV co-infected 
patients (Koul et al., 2011). 
 
Furthermore, investment in TB drug research and development is insufficient relative 
to the burden of this disease. The 2013 Report on Tuberculosis Research Funding 
Trends, 2005-2012 revealed that the funding for TB R&D was cut by US$30.4 
million in 2012 compared with the previous year (Frick and Jiménez-Levi, 2013). 
The private sector also reduced their funding by 22.1% (Burki, 2014). The pullout of 
major pharmaceutical companies such as Pfizer and AstraZeneca from this field in 
the past year brought a big impact to global TB research (Lessem, 2014). 
Pharmaceutical investments were likely to drop further in the next few years.     
 
 
1.1.5 New drugs in pipeline 
For the first time in nearly five decades, a promising TB drug pipeline has emerged. 
A number of new and repurposed therapeutic agents are under investigation and in 
phase I to phase III clinical trials (Lienhardt et al., 2012). These include novel 
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chemical entities as well as the known drugs that are used to treat other diseases. By 
combining the new candidates with the existing TB drugs it is hoped that the 
treatment duration can be reduced and TB drug-resistant strains can be cured.     
 
The Global Alliance for TB Drug Development is currently evaluating the feasibility 
of  a fluoroquinolone-based regimen to reduce the treatment duration of drug-
susceptible TB from 6 months to 4 months (Burki, 2014). Later-generation of 
fluoroquinolones such as gatifloxacin and moxifloxacin (Figure 1.7) have been 
proved to possess high efficacy and safety in MDR-TB treatment (Kwon et al., 2014). 
Rifapentine (Figure 1.7) has been tested in a combination with isoniazid at phase III 
clinical trial. However this regimen showed high failure rates in HIV-positive 
patients as well as those with cavitary pulmonary TB (Benator et al., 2002). 
Linezolid (Figure 1.7), a first generation of oxazolidinone in phase II, has the 
potential to treat MDR/XDR-TB, but its significant toxicity limits its long-term use 
(Kwon et al., 2014).           
 
 
12 
 
 
 
Figure 1.7 Chemical structures of potential TB drugs in clinical development.  
 
 
Bedaquiline (Figure 1.8) represents the first antitubercular drug to be approved for 
the past 40 years after rifampicin. It inhibits mycobacterial adenosine triphosphate 
(ATP) synthase, a key enzyme in the energy metabolism of Mtb (Haagsma et al., 
2011). It was granted accelerated approval by the US Food and Drug Administration 
(FDA) in 2012 as part of the treatment regimen for MDR-TB based on limited 
efficacy and safety data from Phase II studies (Chan et al., 2013). Therefore WHO 
issued “interim policy guideline” for the usage of bedaquiline when other treatment 
alternatives are not available (World Health Organization, 2013).  
 
Delamanid (Figure 1.8), a novel nitroimidazole-oxazole derivative, is the second new 
drug to receive regulatory approval by the European Medicine Agency in 2014. It is 
suggested by WHO as an interim recommendation to treat adults with MDR-TB 
under conditions when an effective treatment regimen is unavailable  (World Health 
Organization, 2014b). It is a prodrug that blocks the biosynthesis of mycolic acids in 
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Mtb and thus disrupts its cell wall (Zumla et al., 2013). This new drug has only been 
through Phase IIb clinical trial and is currently in pediatrics and Phase III trials 
(Lessem, 2014).  
 
 
 
Figure 1.8 Newly approved drugs for treatment of MDR-TB under “interim 
policy guideline”. 
 
 
1.1.6 Potential drug targets 
Advancements in molecular biology and the development of powerful genetic tools 
have accelerated the rate in discovery of new therapeutic targets. Transposon 
mutagenesis, gene knockout and gene transfer methods have been used recently to 
identify genes that are essential for the survival of Mtb in vitro and in vivo (Zhang et 
al., 2006; Lamichhane et al., 2003). New drugs should be targeting not only on the 
metabolically active Mtb but also to kill the persisters or non-growing bacilli 
(Lamichhane, 2011). Several pathways have been characterized as potential drug 
targets, including cell wall synthesis, energy metabolism pathways and protein 
processing (Zhang, 2005). Genes involved in the mycobacterial persistence, such as 
isocitrate lyase (Sharma et al., 2000), L,D-transpeptidase (Lavollay et al., 2008) and 
DosR (regulator involved in mycobacterial survival under hypoxic conditions (Park 
et al., 2003)), have also been identified as potential targets for new drug development. 
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Figure 1.9 represents a number of targets inhibited by the existing TB drugs as well 
as some potential new targets. 
   
 
 
Figure 1.9 Targets implicated in TB disease (Adapted from Lamichhane, 2011). 
 
Mtb has a unique cell wall that contributes to its pathogenicity (Tonge, 2000). It 
contains a very thick waxy, complex lipid-rich membrane which is highly 
hydrophobic and impermeable, thus helps the bacteria to persist and resistant to 
many chemotherapies (Barry III et al., 1998). Mycobacterial cell wall is composed of 
three covalently linked macromolecules: mycolic acids, peptidoglycan, and 
arabinogalactan. Till date, anti-TB drugs that are currently used include inhibitors of 
mycolic acids (isoniazid and ethionamide), arabinogalactan (ethambutol) and 
peptidoglycan (cycloserine) (Mdluli and Spigelman, 2006).  
 
Mycolic acids are α-alkyl, β-hydroxy branched long chain fatty acids that form the 
protective layer of the cell envelope. To generate these long chain fatty acids, Mtb 
contains both FAS I and FAS II fatty acid biosynthesis systems (de Souza et al., 
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2008). FAS I is responsible for the de novo synthesis of C16-C26 fatty acids; and 
FAS II elongates these fatty acids up to C56 to produce precursors of mycolic acids 
(Mdluli and Spigelman, 2006). Enoyl-ACP reductase, encoded by InhA gene, is 
essential in the last step of elongation cycle in FAS II (Figure 1.10). It catalysed the 
NADH-specific reduction of 2-trans-enoyl ACP (Quemard et al., 1995).  
 
 
 
Figure 1.10 FAS II system in Mycobacterium tuberculosis. 
 
InhA belongs to the short-chain alcohol dehydrogenase/reductase (SDR) superfamily, 
characterized by their catalytic residues tyrosine 158 and lysine 165 (Parikh et al., 
1999). It is now well established that InhA is the primary target of isoniazid (INH), 
one of the most powerful front-line drug for TB treatment. As a prodrug, INH does 
not inhibit InhA directly but must be activated by KatG to form the reactive acyl 
radical. The acyl radical then binds to the position 4 of nicotinamide adenine 
dinucleotide (NAD) to form an active INH-NAD adduct (Zhao et al., 2006). Clinical 
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studies showed that high levels of resistance to INH are caused by mutations in KatG 
(Zhao et al., 2006; Suarez et al., 2009). Therefore inhibitors targeting InhA directly 
without the need of activation would be the promising candidates to develop new 
anti-TB drugs.  
 
 
 
Figure 1.11 Activation of isoniazid (INH) by KatG to form INH-NAD adduct that 
inhibits InhA enzyme. 
 
 
1.2 Drug design 
1.2.1 Overview 
Drugs are defined as chemical substances that are used to prevent and treat diseases 
(Thomas, 2004). Since human life is constantly threatened by many illnesses, it is of 
utmost importance to discover ideal drugs that can benefit humanity. The process of 
drug design and development is challenging, costly and time consuming. It starts 
from identification of a disease and its target, followed by lead discovery and 
optimization, in vitro and animal test, clinical studies in human beings, and finally to 
the regulatory approval and production (Figure 1.12). The average time to bring a 
new drug from research lab to patients is 10-15 years and the estimated cost is 1.3 
billion US dollars (Turner, 2010). In 2013, 27 new molecular entities have been 
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approved by FDA’s center for Drug Evaluation and Research (CDER) as novel new 
drugs (US Food and Drug Administration, 2014). 
 
 
 
Figure 1.12 Process of drug discovery and development (Modified from Nature 
Reviews Drug Discovery (Wenk, 2005, Cooper, 2002)). 
 
The whole process of drug development requires input from various fields, including 
medicinal chemistry, biology, pharmacology, biochemistry and computational 
chemistry (Thomas, 2004). The primary roles of medicinal chemists are to design 
and synthesize new compounds that are deemed suitable for use as drugs, followed 
by biological evaluation and generation of a new hypothesis to further improve the 
design and synthesis (Lowe, 2006).  Methods like addition of functional groups, 
extension of structures, changing the type of substituent as well as its position, etc. 
are the common strategies used in drug design. The biological activity of a 
compound might be varied even with a slight change in the molecular structure. For 
example, by changing the ether linkage -OCH2- of the beta blocker propranolol to -
SCH2-, the activity will be diminished (Patrick, 1995). Therefore chemists usually 
synthesize a series of analogues, evaluate their biological activity and correlate the 
chemical structures with the optimum activity.  
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With the greater advancement and understanding of biochemical structures and 
physiological mechanisms, drugs can be designed using a “rational approach” 
(Pandeya and Dimmock, 1997). This approach takes into account the targets or sites 
of drug action so that drugs can be designed accordingly. The first rational 
development of synthetic drugs was started by Paul Ehrlich and Sacachiro Hata in 
1910. They produced the antiprotozoal arshemamine by combining synthesis with 
reliable biological screening and evaluation procedures (Thomas, 2004). Today, 
rational drug design can be organized into four areas: pharmacophore-based and 
structure-based approaches which depend on whether the three-dimensional structure 
of the protein target is known; new lead generation and structure evaluation which 
can be performed regardless of the availability of the biological target structure 
(Reddy and Parrill Abby, 1999). This is where the analysis of structure-activity 
relationship (SAR), quantitative structure-activity relationship (QSAR), de novo 
design and combinatorial chemistry come in place.   
 
Drug design and development is a multi-disciplinary field that requires scientists 
from different areas to work together to construct a virtual drug with desired 
chemical, biological and physical properties (Neamati and Barchi, 2002). In this 
postgenomic era, numerous novel and exciting techniques in proteomics, 
bioinformatics and genomic sequencing have been developed and implemented in 
the process of drug discovery for the past 5-10 years. Academic, healthcare, 
government and industrial sectors should collaborate and work hand in hand to drive 
the advancements from genetic and biological research into medical and commercial 
benefits for society (Hoelder et al., 2012). 
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1.2.2 Green chemistry in drug discovery 
The term “green chemistry” is defined as the design of chemical products and 
processes that minimize or eliminate the use and production of hazardous substances 
(Anastas and Kirchhoff, 2002). It was conceptualised by Paul T. Anastas of the US 
Environmental Protection Agency (EPA) in 1993. Since then the field of green 
chemistry has been incorporated into many key research areas including catalysis, 
design of environmentally benign solvents, development of renewable feedstocks, 
usage of safer chemicals etc (Anastas and Kirchhoff, 2002). Twelve principles of 
green chemistry have been developed to provide a guideline of what would make a 
greener process, product or system (Anastas and Warner, 2000). 
 
Chemical reactions play an important role in drug synthesis. Many of the traditional 
synthetic methods have broad scope but at the same time produce massive amounts 
of waste. The pharmaceutical industry has made significant efforts to minimize the 
usage of hazardous solvents and to reuse the catalysts to improve atom economy and 
environmental safety (Smita and Falguni, 2012). One of the most classical examples 
of how green chemistry can be applied in drug synthesis is the production of 
ibuprofen (Sheldon, 2010). As shown in Figure 1.13, the conventional method 
required a 6-step procedure with stoichiometric reagents, low atom efficiency, and 
production of secondary by-products and waste. In contrast, the green alternative 
developed in 1990s involved only three catalytic steps with increased efficiency and 
sustainability (Elango et al., 1991; Poliakoff and Licence, 2007). Most of the atoms 
of the reactants are incorporated into the desired product and unwanted by-products 
are reduced up to ten times. 
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Figure 1.13 Synthesis of ibuprofen by using conventional six-step method (A) and 
the green synthesis that was reduced to three steps (B). 
 
 
Researchers and pharmaceutical companies should be encouraged to utilize green 
chemistry procedures in drug discovery. Green solvents including water, liquid 
polymers, ionic liquids and supercritical fluids have great potential to contribute to 
more sustainable process (Leitner, 2009). Appropriate catalysts such as zeolites and 
montmorillonite clay are reusable, economically favourable and more environmental 
friendly (Kaneda et al., 2002). Some “green” reactions such as solvent-free 
microwave-assisted synthesis, grinding method and multicomponent one-pot 
reactions are also been used and promoted. 
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1.2.3 1,3-dipolar cycloaddition 
In modern drug design, chemists are constantly working on to discover new and 
improved reactions to explore novel pharmacological agents. One of the major 
challenges of this research is the development of new transformations that are not 
only efficient, selective and high yield but also environmental friendly (Hazra et al., 
2013). Tandem reactions, or sometimes known as domino, cascade, consecutive, 
iterative or one-pot reactions, link several transformations together in a single 
synthetic step (Bunce, 1995). Over the past decade, tandem reactions are of immense 
importance because they increase the synthetic efficacy to construct complex organic 
molecules without the needs to isolate and purify the intermediates. This helps in 
substantial minimization of waste, time, cost and labour (Li et al., 2008). Therefore it 
can be considered as a form of “green chemistry” (Li et al., 2008; Nicolaou et al., 
2006).  
 
1,3-dipolar cycloaddition, also known as the Huisgen cycloaddition, is a classical 
tandem reaction  in organic chemistry. It consists of the reactions of 1,3-dipoles with 
olefinic or acetylenic dipolarophiles to construct various highly substituted five-
membered rings in a regio- and stereoselective manner (Tsuge and Kanemasa, 1989; 
Manian et al., 2006). 1,3-dipole is a species that is represented by zwitterionic octet 
structure where the central atom must have an electron pair to stabilize the species by 
dispersal of the positive charge (Padwa, 1984). Dipolarophiles, on the other hand, are 
compounds that react with 1,3-dipole and they are typically alkenes or alkynes. The 
history of 1,3-dipoles traces back to 1883 when Theodor Curtius discovered 
diazoacetic ester. However it was only generalized in 1960s when Rolf Huisgen first 
established its synthetic application through systematic studies (Padwa, 1984). Today 
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this reaction is widely practised in many areas, from material chemistry (Lutz, 2007), 
bioconjugation (Dirks et al., 2009), nanotechnology (Zhou et al., 2008) to drug 
discovery (Najera and Sansano, 2009). 
 
 
 
Figure 1.14 General scheme of 1,3-dipolar cycloaddition. 
 
There are two types of mechanisms in 1,3-dipolar cycloaddition: concerted and step-
wise. These mechanisms had been controversially debated in the late 1960s by 
Huisgen (Huisgen, 1968) and Firestone (Firestone, 1968). The concerted mechanism 
which was postulated by Huisgen, is thermally allowed with [π4s + π2s] according to 
the Woodward-Hoffmann rules. This involves 4 π electrons from the dipole and 2 π 
electrons from the dipolarophile. Three pz orbitals of the 1,3-dipole and two pz 
orbitals of the dipolarophile will combine suprafacially, and the stereochemistry of 
the reactants could then be transferred to the product. (Gothelf and Jørgensen, 1998). 
Step-wise biradical mechanism that was suggested by Firestone involved a two-step 
reaction with a discrete intermediate, a spin-paired diradical. The stereochemical 
information was thus destroyed during these transformations (Firestone, 1968). 
However this free radical mechanism was overwhelmed by the concerted mechanism 
and is no longer in favour (Quin and Tyrell, 2010). 
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The simple and easy accessible procedures of 1,3-dipolar cycloaddition reaction 
makes it a useful tool in constructing biologicaly important nitrogen-containing five-
membered heterocycles such as pyrrolidines, oxindoles and isoxazolines (Figure 
1.15). Fokas et al. (1998) reported the formation of spiro[pyrrolidine/oxindole] ring 
system through three component 1,3-dipolar cycloaddition using isatin, α-amino 
acids and chalcones. Dürüst et al. (2011) reported the regioselective 1,3-dipolar 
cycloaddition of phenanthrolinium ylides with (Z)-arylidene oxazolones. Xiao et al. 
(2013) also successfully synthesized the novel dispirooxindole, pyrrolo(spiro-[2.3′]-
oxindole)-spiro-[4.3″]-oxindole via this reaction. All of these examples were 
depicted in Figure 1.16.  
 
 
 
Figure 1.15 Examples of 1,3-dipolar cycloadditions in constructing various types 
of 5-membered heterocyclic compounds. 
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Figure 1.16 Known synthetic routes of different cycloadducts that have been 
published previously (Fokas et al, 1998; Dürüst et al., 2011; Xiao et 
al.).   
 
 
1.2.4 Molecular docking in drug design 
Molecular docking is an essential tool in structural molecular biology and computer-
aided drug design (Morris and Lim-Wilby, 2008). It plays an important role in 
understanding drug-receptor interactions. The first docking algorithm for small 
molecules was developed in 1982 by the Kuntz group from University of California, 
San Francisco (Kuntz et al., 1982). Today, the increased availability of three 
